DiaCarta Revenue and Competitors

Claim your profile



Total Funding



Estimated Revenue & Valuation

  • DiaCarta's estimated annual revenue is currently $4.4M per year.(i)
  • DiaCarta received $45.0M in venture funding in February 2018.
  • DiaCarta's estimated revenue per employee is $77,500
  • DiaCarta's total funding is $53M.

Employee Data

  • DiaCarta has 57 Employees.(i)
  • DiaCarta grew their employee count by -8% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

DiaCarta is a translational genomics and personalized diagnostics company that provides ultra-sensitive detection tools for cancer diagnosis, therapy identification and prognosis monitoring. Our mission is to provide ultra-sensitive and advanced technologies that will redefine the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world. To learn more, visit http://www.diacarta.com.

keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





DiaCarta News

2022-04-20 - Global T-Cell Therapy Market Scope And Forecast | AbbVie ...

Amgen; Bluebird Bio; Celgene Corporation; Cellectis; DiaCarta; Fate Therapeutics; Gilead Sciences; Juno Therapeutics; Kite Pharma; Merck; Novartis; Pfizer...

2022-03-30 - DiaCarta Expands Board Leadership with Industry Veteran

PLEASANTON, Calif. , April 7, 2022 /PRNewswire/ -- DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel...

2022-03-22 - Developing Novel Liquid Biopsy Oncology Tests

AZ: DiaCarta is a molecular diagnostics company borne out of decades of research in next-generation sequencing (NGS), circulating cell-free DNA...

2019-01-17 - CIO Bulletin Announces DiaCarta Inc. As One of the 30 ...

RICHMOND, Calif.--(BUSINESS WIRE)--DiaCarta today announced that CIO Bulletin has named it among the 30 Fastest Growing Companies ...

2018-10-15 - DiaCarta, Inc., Awarded $2 Million NCI Contract to Pursue ...

BUSINESS WIRE)--DIACARTA, Inc., a precision diagnostic company and leading developer of products for nucleic acid-based detection ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

DiaCarta Funding

DateAmountRoundLead InvestorsReference
2018-02-13$45.0MBFortune Fountain CapitalArticle